Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: Data from the PROMEtheuS project, a multicentre European prospective study

BJU International

Volumn 115, Issue 4, 2015, Pages 537-545

  Abrate, Alberto ^a   Lazzeri, Massimo ^a   Lughezzani, Giovanni ^a   Buffi, Nicolòmaria ^a   Bini, Vittorio ^c   Haese, Alexander ^d   De La Taille, Alexandre ^e   McNicholas, Thomas ^f   Redorta, Joan Palou ^g   Gadda, Giulio M ^a   Lista, Giuliana ^a   Kinzikeeva, Ella ^a   Fossati, Nicola ^a   Larcher, Alessandro ^a   Dell'Oglio, Paolo ^a   Mistretta, Francesco ^a   Freschi, Massimo ^b   Guazzoni, Giorgio ^a  

^a Division of Oncology Unit of Urology URI   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Department of Digestive Surgery Mondor Hospital APHP   (France)

^f LISTER HOSPITAL   (United Kingdom)

^g FUNDACIÓ PUIGVERT   (Spain)

Author keywords

obesity; prostate biopsy; prostate health index; prostate specific antigen; 2 proPSA

Indexed keywords

FREE PROSTATE SPECIFIC ANTIGEN; PRO 2 PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EUROPEAN; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT DISEASE ASSESSMENT; AGED; CANCER GRADING; CASE CONTROL STUDY; CLINICAL TRIAL; HEALTH STATUS INDICATOR; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE; PROSTATIC NEOPLASMS;

AGED; CASE-CONTROL STUDIES; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; OBESITY; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84925674761     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12907     Document Type: Article

References (31)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
2. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004; 101 (Suppl.): 2371-2490
3. Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN,. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008; 8: 200
4. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-781
5. Jentzmik F, Schnoeller TJ, Cronauer MV, et al. Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage. Int J Urol 2014; 21: 980-986
6. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED,. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 2005; 65: 708-712
7. Chamie K, Oberfoell S, Kwan L, Labo J, Wei JT, Litwin MS,. Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy? Urology 2013; 81: 949-955
8. Oh JJ, Jeong SJ, Lee BK, et al. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy. BJU Int 2013; 112: E265-271
9. Hedelin H, Johansson N, Stroberg P,. Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J Urol Nephrol 2005; 39: 154-159
10. Roehrborn CG, Pickens GJ, Carmody T 3rd,. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology 1996; 47: 59-66
11. Jansen FH, van Schaik RH, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921-927
12. Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013; 63: 986-994
13. Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013; 112: 313-321
14. Lughezzani G, Lazzeri M, Larcher A, et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 2012; 188: 1144-1150
15. Lazzeri M, Lughezzani G, Larcher A, et al. Reply to Sergey Tadtayev, Thomas A. McNicholas, and Gregory B. Boustead's Letter to the Editor re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61:455. Eur Urol 2012; 62: e16
16. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-1242
17. Aronne LJ,. Classification of obesity and assessment of obesity-related health risks. Obes Res 2002; 10 (Suppl. 2): 105S
18. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845
19. Vickers AJ, Elkin EB,. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26: 565-574
20. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011; 377: 557-567
21. Nomura AM,. Body size and prostate cancer. Epidemiol Rev 2001; 23: 126-131
22. Bhindi B, Kulkarni GS, Finelli A, et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol 2014; 66: 841-848
23. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ,. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638
24. Chalfin HJ, Lee SB, Jeong BC, et al. Obesity and long-term survival after radical prostatectomy. J Urol 2014; 192: 1100-1104
25. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983
26. Freedland SJ, Platz EA, Presti JC Jr, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006; 175: 500-504
27. Bañez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-2280
28. Bañez LL, Albisinni S, Freedland SJ, Tubaro A, De Nunzio C,. The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. World J Urol 2014; 32: 323-328
29. Lazzeri M, Briganti A, Scattoni V, et al. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol 2012; 188: 1137-1143
30. Fossati N, Lazzeri M, Haese A, et al. Clinical performance of serum isoform [-2]proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age: results from a multicentric European study. BJU Int 2014. [Epub ahead of print]. doi: 10.1111/bju.12718
31. Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond) 2010; 34: 791-799